Fierce JPM Week 2025 - Virtual

In the dynamic world of biotech, incubators, accelerators, and co-working spaces have become crucial ecosystems that nurture the growth of early-stage biotech companies. These innovative environments are designed to help emerging companies overcome the myriad challenges they face in developing groundbreaking therapies and diagnostics that enhance health outcomes.

As a biotech entrepreneur or stakeholder, you understand the importance of minimizing large capital investments in infrastructure and lab space. The bio-innovation ecosystem does just that, while simultaneously fostering a collegial atmosphere that sparks creativity and collaboration. Within this ecosystem, some hosts offer shared core lab facilities, coaching, guidance, and access to investment, all of which are pivotal to your success.

Join us for an exclusive fireside chat with Matt Dunleavy, Director of Global Commercial Strategy, and Mark Federici, Global Director of Bio-innovation at Thermo Fisher Scientific’s Biosciences business. This is your opportunity to gain insights into the capabilities and value that your choice of supplier can potentially bring to the ecosystem. Through real-world case studies, you will learn how biotech incubators have effectively collaborated with Thermo Fisher to achieve remarkable outcomes.

Don’t miss this chance to discover how you can leverage these collaborations to propel your biotech ventures forward.

Explore practical and flexible approaches to clinical trial partnerships, focusing on risk-sharing models that reduce financial burdens while fostering collaboration and commercial success.

Key Highlights:

• Performance-Based Models: Share financial risks with clear goals and incentives for strategic alignment.
•  Revenue Sharing for Biotech: Support smaller firms and innovative therapies with shared financial burdens and future revenue potential.
•  Hybrid Approaches: Combine milestone-based payments with revenue-sharing elements to balance commitment and flexibility.

The right real-world data can make a difference at every stage of the life sciences product life cycle – from market research and clinical trial design to go-to-market and commercialization strategies. And the right technology should deliver a unified platform experience and single source of truth across the enterprise for high-fidelity patient insights, streamlined operations, aligned decision-making, and improved therapeutic options for patients.

Join Arif Nathoo (CEO and Co-Founder of Komodo Health) and Jorge Santos da Silva (CEO and Co-Founder of MoonLake Immunotherapeutic) for a discussion on how emerging biotechs and life sciences giants alike can harness the power of a unified platform powered by regulatory-grade real-world data to transform business strategy and deliver transformative treatments to patients in need.